Drug Approval | February 25, 2023
Cipla has received 8 inspectional observations in Form 483
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
The company has been issued ‘Form 483’ with two observations
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
Global pharmaceutical company having a surgical business concept incepted in Dubai
The product is backed by required scientific proof and comparative bioequivalence studies
Subscribe To Our Newsletter & Stay Updated
